Pfizer will initiate a clinical trial for its respiratory syncytial virus (RSV) infection drug sisunatovir in adults in Korea. The company had previously initiated a trial for the drug on pediatric patients in Korea.

On the 7th, the Ministry of Food and Drug Safety (MFDS) approved Pfizer's "interventional Phase II/III, adaptive, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of oral sisunatovir with placebo in non-hospitalized adults with symptomatic respiratory syncytial virus infection at risk of progression to severe disease.”

The trial will be conducted in Chungnam National University Hospital, Korea University Medicine, Chilgok Kyungpook Na